CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted
therapies, announced today it will present 14 posters and two
symposiums highlighting new scientific insights from its ATTR
amyloidosis portfolio at the 3rd European ATTR
Amyloidosis (EU-ATTR) meeting for Patients and Doctors on
September 6-8, 2021. The posters and
symposiums will include several presentations about Ionis' ATTR
medicines, including its investigational antisense medicine,
eplontersen, which is currently being evaluated in two phase 3
trials to potentially treat transthyretin amyloid cardiomyopathy
(ATTR-CM) and polyneuropathy (ATTR-PN). The presentations
underscore Ionis' commitment to the ATTR amyloidosis community and
the company's important work toward advancing treatment options for
people impacted by the disease.
The following is a schedule of Ionis' events and activities
to be held virtually at EU-ATTR:
- Tuesday, Sept. 7 at
2:00 p.m. – 2:15 p.m. CEST
Presentation: Gustavo Buchele, M.D., Ph.D., executive
director, clinical development at Ionis, will present study design
and trial details for CARDIO-TTRansform, which is currently
enrolling, on the Patients Association Channel.
- Wednesday, Sept. 8 at
2:00 p.m. – 2:45 p.m. CEST
Satellite Symposium:
Sotirios "Sam" Tsimikas, M.D., senior vice president, clinical
development and cardiovascular franchise leader at Ionis, is
moderating a satellite symposium about ATTR-CM and investigational
antisense medicine, eplontersen, for Ionis' CARDIO-TTRansform
Study, on the Doctors Channel. He will be joined by renowned
cardiologists, Marianna Fontana,
M.D., Ph.D., and Ahmad Masri, M.D.,
M.S. The event will discuss the landscape and future of ATTR-CM
treatment and how Ionis aims to potentially change the standards of
care with its novel LICA technology.
The following posters will be available to congress attendees at
the start of the meeting:
- Evaluation of the Efficacy and Safety of Eplontersen in
Patients with Transthyretin-Mediated Amyloid Cardiomyopathy: The
CARDIO-TTRansform Study
- Caregiving Burden Among Caregivers of Patients with ATTR
Amyloidosis
- Comparison of Symptoms Experienced by Patients with ATTRwt and
hATTR: Findings from the Development of an ATTR-Specific Patient
Reported Outcomes
- Patient-Reported Outcomes by Time from Symptom Onset to First
Pharmacotherapy Among Transthyretin Amyloidosis Patients
- Clinical Characteristics of Patients with Mutations Associated
with Hereditary Transthyretin Amyloidosis Versus Those Associated
with Other Inherited Cardiovascular Diseases: Insights from a
Genetic Testing Programme
- Comparison of Patients with Mutations Associated with
Hereditary Transthyretin Amyloidosis Versus Those Associated with
Other Neuromuscular Diseases
- Three Newly Recognized Likely Pathogenic Variants of The TTR
Gene Causing Hereditary Transthyretin Amyloidosis
- Cardiovascular Symptom Burden Prior to Diagnosis of
Transthyretin Amyloid Cardiomyopathy Among Medicare
Beneficiaries
- The Patient Journey Prior to Diagnosis of Hereditary
Transthyretin Amyloidosis
- Long-Term Efficacy and Safety of Inotersen for Hereditary
Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 3-Year
Update
- Inotersen on Neuropathy Symptom and Change Scores in Hereditary
Transthyretin Amyloidosis: Subgroups and Responder Analyses
- Efficacy of Inotersen for Neuropathic Impairment Scores in
Patients with Hereditary Transthyretin Amyloidosis with
Polyneuropathy
- Responder Analyses Examining the Impact of Inotersen on
Neuropathic Impairment Score in Patients with Hereditary
Transthyretin Amyloidosis with Polyneuropathy
- Treatment Satisfaction for Gene Silencing Pharmacotherapies in
Hereditary Transthyretin Amyloidosis with Polyneuropathy
Details on presentation times can be found on the program
website.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in
RNA-targeted therapy, pioneering new markets and changing standards
of care with its novel antisense technology. Ionis currently has
three marketed medicines and a premier late-stage pipeline
highlighted by industry-leading neurological and cardiometabolic
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision of
becoming one of the most successful biotechnology companies.
To learn more about Ionis, visit www.ionispharma.com and
follow us on twitter @ionispharma.
Ionis' Forward-looking Statement
This press release includes forward-looking statements regarding
Ionis' business, and the therapeutic and commercial potential of
Ionis' technologies and products in development. Any statement
describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, including those related
to the impact COVID-19 could have on our business, and including
but not limited to those related to our commercial products and the
medicines in our pipeline, and particularly those inherent in the
process of discovering, developing and commercializing medicines
that are safe and effective for use as human therapeutics, and in
the endeavor of building a business around such medicines. Ionis'
forward-looking statements also involve assumptions that, if they
never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements.
Although Ionis' forward-looking statements reflect the good
faith judgment of its management, these statements are based only
on facts and factors currently known by Ionis. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Ionis' programs are described in
additional detail in Ionis' annual report on Form 10-K for the year
ended December 31, 2020, and the most
recent Form 10-Q quarterly filing, which are on file with the SEC.
Copies of these and other documents are available from the
Company.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-to-host-attr-symposium-highlighting-cardio-ttransform-study-at-3rd-european-attr-amyloidosis-meeting-301368874.html
SOURCE Ionis Pharmaceuticals, Inc.